Treatment for liver metastases from breast cancer: Results and prognostic factors

Table 1 Basic clinical data between the two groups.

Factors	A group	B group	P
Age (yr)	53.13±9.23	55.65±12.32	0.412
The type of primary breast cancer infiltrating ductal carcinoma/simple carcinoma/adenocarcinoma	26/0/2	18/2/0	0.12
Method of treatment for primary tumor surgery/postoperative radiotherapy/postoperative chemotherapy	28/10/27	20/9/20	0.911
Interval time between the primary tumor and metastasis (mo)	31.21±24.56	27.23±22.97	0.11
Number of liver metastasis single/multi	9/19	5/15	0.591
Stage of liver metastasis
I/II/III/IV	10/10/6/2	10/6/3/1	0.794

Criteria of liver metastasis staging see Gennari’s staging system[15]. A group: TACE group; B group: systemic chemotherapy group.

Table 2 Comparison of treatment responses between the groups.

	A group (n = 28)		B group (n = 20)
	No of patients	%	No of patients	%
Overall response	10	35.7	2	10
Complete response	2	7.1	0	0
Partial response	8	28.6	2	10
Stable disease	13	46.4	7	35
Progressive disease	5	17.9	11	55

Table 3 Side effects between the two groups.

Side effects	A group		B group
	Grade 1/2	Grade 3/4	Grade 1/2	Grade 3/4
Leukopenia	3	0	6	3
Hypochromia	3	0	4	1
Thrombocytopenia	2	0	4	1
Reaction of GI system	1	0	3	1
Impairment of liver function	5	0	2	0
Impairment of renal function	0	0	1	0

Table 4 Multivariate analysis of prognostic factors of patients with BCLM.

Factors	Gradings	Regression coefficient	Standard error	Chi-square	P
Child-Pugh grade	A gradeB or C grade	2.283	0.712	10.683	0.001
Clinical stage of liver metastases	I+II stageIII+IV stage	-0.452	0.273	9.118	0.0054
Lymph node status of the primary cancer	N0 N1+N2	0.177	0.080	4.548	0.0287
Loss of weight	Yes No	0.435	0.210	4.297	0.0392
Intervals between the primary to the metastases	≤48 mo >48 mo	0.012	0.158	0.024	0.886